Abstract
Background: Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer and the fourth leading cause of cancer death in the world.
Aims: This study aimed to investigate the efficacy and safety of Lenvatinib + PD-1 inhibitor + TACEHAIC (LePTaHAIC) versus Sorafenib + TACE (SorTACE) for patients with intermediate and advanced HCC.
Methods: In this retrospective study, patients diagnosed with BCLC stage B/C HCC were included. All patients were treated with LePTaHAIC (LePTaHAIC group) or SorTACE (SorTACE group) between September 2019 and September 2020. Outcomes, including progression-free survival (PFS), conversion surgical resection rate, objective remission rate (ORR), overall survival (OS), and treatment-related adverse events (AEs) were analyzed and compared between the two treatment modalities.
Results: In total, 65 eligible patients were recruited, with 35 assigned to receive LePTaHAIC and 30 assigned to undergo SorTACE. Median PFS (11.4 vs. 5.13 months) and OS (26 vs. 10.08 months) in the LePTaHAIC group were significantly higher compared to the SorTACE group (both P < 0.0001). The ORR (mRECIST standard) of the LePTaHAIC group was markedly higher compared to the SorTACE group (71.4% vs. 40%, P = 0.01). In the LePTaHAIC group, 11 patients underwent surgical resection (BCLC stage B: n = 4, BCLC stage C: n = 7) and 3 patients achieved complete pathological remission (pCR), while one patient in the SorTACE group underwent surgical resection. The conversion surgical resection rate of the LePTaHAIC group was significantly higher compared to the SorTACE group [31.4% (11/35) vs. 3.3% (1/30), P = 0.004]. Patients with LePTaHAIC had more frequent grade 3-4 treatmentrelated AEs, especially thrombocytopenia, compared to the SorTACE group (22.9% vs. 3.3%, P = 0.02).
Conclusion: LePTaHAIC exhibited acceptable toxic effects and improved survival compared to SorTACE in intermediate and advanced HCC.
[1]
Wong, M.C.S.; Jiang, J.Y.; Goggins, W.B.; Liang, M.; Fang, Y.; Fung, F.D.H.; Leung, C.; Wang, H.H.X.; Wong, G.L.H.; Wong, V.W.S.; Chan, H.L.Y. International incidence and mortality trends of liver cancer: A global profile. Sci. Rep., 2017, 7(1), 45846.
[http://dx.doi.org/10.1038/srep45846] [PMID: 28361988]
[http://dx.doi.org/10.1038/srep45846] [PMID: 28361988]
[2]
Yang, Q.; Sun, C.; Sheng, Y.; Chen, W.; Deng, C. The biomarkers for predicting viral hepatitisassociated hepatocellular carcinoma. Turk. J. Gastroenterol., 2022, 33(1), 1-7.
[http://dx.doi.org/10.5152/tjg.2022.19813] [PMID: 35040782]
[http://dx.doi.org/10.5152/tjg.2022.19813] [PMID: 35040782]
[3]
Raoul, J.L.; Forner, A.; Bolondi, L.; Cheung, T.T.; Kloeckner, R.; de Baere, T. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat. Rev., 2019, 72, 28-36.
[http://dx.doi.org/10.1016/j.ctrv.2018.11.002] [PMID: 30447470]
[http://dx.doi.org/10.1016/j.ctrv.2018.11.002] [PMID: 30447470]
[4]
Raoul, J.L.; Sangro, B.; Forner, A.; Mazzaferro, V.; Piscaglia, F.; Bolondi, L.; Lencioni, R. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat. Rev., 2011, 37(3), 212-220.
[http://dx.doi.org/10.1016/j.ctrv.2010.07.006] [PMID: 20724077]
[http://dx.doi.org/10.1016/j.ctrv.2010.07.006] [PMID: 20724077]
[5]
Kudo, M.; Matsui, O.; Izumi, N.; Iijima, H.; Kadoya, M.; Imai, Y.; Okusaka, T.; Miyayama, S.; Tsuchiya, K.; Ueshima, K.; Hiraoka, A.; Ikeda, M.; Ogasawara, S.; Yamashita, T.; Minami, T.; Yamakado, K. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the liver cancer study group of Japan. Liver Cancer, 2014, 3(3-4), 458-468.
[http://dx.doi.org/10.1159/000343875] [PMID: 26280007]
[http://dx.doi.org/10.1159/000343875] [PMID: 26280007]
[6]
He, M.K.; Zou, R.H.; Li, Q.J.; Zhou, Z.G.; Shen, J.X.; Zhang, Y.F.; Yu, Z.S.; Xu, L.; Shi, M. Phase II study of sorafenib combined with concurrent hepatic arterial infusion of oxaliplatin, 5-fluorouracil and leucovorin for unresectable hepatocellular carcinoma with major portal vein thrombosis. Cardiovasc. Intervent. Radiol., 2018, 41(5), 734-743.
[http://dx.doi.org/10.1007/s00270-017-1874-z] [PMID: 29327075]
[http://dx.doi.org/10.1007/s00270-017-1874-z] [PMID: 29327075]
[7]
He, M.K.; Le, Y.; Li, Q.J.; Yu, Z.S.; Li, S.H.; Wei, W.; Guo, R.P.; Shi, M. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: A prospective non-randomized study. Chin. J. Cancer, 2017, 36(1), 83.
[http://dx.doi.org/10.1186/s40880-017-0251-2] [PMID: 29061175]
[http://dx.doi.org/10.1186/s40880-017-0251-2] [PMID: 29061175]
[8]
Guo, W.; Gao, J.; Zhuang, W.; Wu, Z.; Li, B.; Chen, S. Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: A propensity score‐matching cohort study. JGH Open, 2020, 4(3), 477-483.
[http://dx.doi.org/10.1002/jgh3.12285] [PMID: 32514457]
[http://dx.doi.org/10.1002/jgh3.12285] [PMID: 32514457]
[9]
Kudo, M.; Finn, R.S.; Qin, S.; Han, K.H.; Ikeda, K.; Piscaglia, F.; Baron, A.; Park, J.W.; Han, G.; Jassem, J.; Blanc, J.F.; Vogel, A.; Komov, D.; Evans, T.R.J.; Lopez, C.; Dutcus, C.; Guo, M.; Saito, K.; Kraljevic, S.; Tamai, T.; Ren, M.; Cheng, A.L. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet, 2018, 391(10126), 1163-1173.
[http://dx.doi.org/10.1016/S0140-6736(18)30207-1] [PMID: 29433850]
[http://dx.doi.org/10.1016/S0140-6736(18)30207-1] [PMID: 29433850]
[10]
Daskivich, T.J.; Belldegrun, A. Words of wisdom. Re: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. Eur. Urol., 2015, 67(4), 816-817.
[http://dx.doi.org/10.1016/j.eururo.2014.12.052] [PMID: 25765212]
[http://dx.doi.org/10.1016/j.eururo.2014.12.052] [PMID: 25765212]
[11]
El-Khoueiry, A.B.; Sangro, B.; Yau, T.; Crocenzi, T.S.; Kudo, M.; Hsu, C.; Kim, T.Y.; Choo, S.P.; Trojan, J.; Welling, T.H., III; Meyer, T.; Kang, Y.K.; Yeo, W.; Chopra, A.; Anderson, J.; dela Cruz, C.; Lang, L.; Neely, J.; Tang, H.; Dastani, H.B.; Melero, I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet, 2017, 389(10088), 2492-2502.
[http://dx.doi.org/10.1016/S0140-6736(17)31046-2] [PMID: 28434648]
[http://dx.doi.org/10.1016/S0140-6736(17)31046-2] [PMID: 28434648]
[12]
Finn, R.S.; Ikeda, M.; Zhu, A.X.; Sung, M.W.; Baron, A.D.; Kudo, M.; Okusaka, T.; Kobayashi, M.; Kumada, H.; Kaneko, S.; Pracht, M.; Mamontov, K.; Meyer, T.; Kubota, T.; Dutcus, C.E.; Saito, K.; Siegel, A.B.; Dubrovsky, L.; Mody, K.; Llovet, J.M. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J. Clin. Oncol., 2020, 38(26), 2960-2970.
[http://dx.doi.org/10.1200/JCO.20.00808] [PMID: 32716739]
[http://dx.doi.org/10.1200/JCO.20.00808] [PMID: 32716739]
[13]
He, M.K.; Liang, R.B.; Zhao, Y.; Xu, Y.J.; Chen, H.W.; Zhou, Y.M.; Lai, Z.C.; Xu, L.; Wei, W.; Zhang, Y.J.; Chen, M.S.; Guo, R.P.; Li, Q.J.; Shi, M. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. Ther. Adv. Med. Oncol., 2021, 13.
[http://dx.doi.org/10.1177/17588359211002720] [PMID: 33854567]
[http://dx.doi.org/10.1177/17588359211002720] [PMID: 33854567]
[14]
Li, B.; Qiu, J.; Zheng, Y.; Shi, Y.; Zou, R.; He, W.; Yuan, Y.; Zhang, Y.; Wang, C.; Qiu, Z.; Li, K.; Zhong, C.; Yuan, Y. Conversion to resectability using transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for initially unresectable hepatocellular carcinoma. Annals of Surgery Open, 2021, 2(2), e057.
[http://dx.doi.org/10.1097/AS9.0000000000000057]
[http://dx.doi.org/10.1097/AS9.0000000000000057]
[15]
Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, L.H.; Sargent, D.; Ford, R.; Dancey, J.; Arbuck, S.; Gwyther, S.; Mooney, M.; Rubinstein, L.; Shankar, L.; Dodd, L.; Kaplan, R.; Lacombe, D.; Verweij, J. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer, 2009, 45(2), 228-247.
[http://dx.doi.org/10.1016/j.ejca.2008.10.026] [PMID: 19097774]
[http://dx.doi.org/10.1016/j.ejca.2008.10.026] [PMID: 19097774]
[16]
He, M.; Li, Q.; Shi, M. Potential areas of interest in a trial of sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin for hepatocellular carcinoma—in reply. JAMA Oncol., 2019, 5(12), 1806-1807.
[http://dx.doi.org/10.1001/jamaoncol.2019.4058] [PMID: 31600361]
[http://dx.doi.org/10.1001/jamaoncol.2019.4058] [PMID: 31600361]
[17]
Gauci, M.L.; Lanoy, E.; Champiat, S.; Caramella, C.; Ammari, S.; Aspeslagh, S.; Varga, A.; Baldini, C.; Bahleda, R.; Gazzah, A.; Michot, J.M.; Postel-Vinay, S.; Angevin, E.; Ribrag, V.; Hollebecque, A.; Soria, J.C.; Robert, C.; Massard, C.; Marabelle, A. Long-term survival in patients responding to Anti–PD-1/PD-L1 therapy and disease outcome upon treatment discontinuation. Clin. Cancer Res., 2019, 25(3), 946-956.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-0793] [PMID: 30297458]
[http://dx.doi.org/10.1158/1078-0432.CCR-18-0793] [PMID: 30297458]
[18]
Kitai, S.; Kudo, M.; Nishida, N.; Izumi, N.; Sakamoto, M.; Matsuyama, Y.; Ichida, T.; Nakashima, O.; Matsui, O.; Ku, Y.; Kokudo, N.; Makuuchi, M. Survival benefit of locoregional treatment for hepatocellular carcinoma with advanced liver cirrhosis. Liver Cancer, 2016, 5(3), 175-189.
[http://dx.doi.org/10.1159/000367765] [PMID: 27493893]
[http://dx.doi.org/10.1159/000367765] [PMID: 27493893]
[19]
Castet, F.; Willoughby, C.E.; Haber, P.K.; Llovet, J.M. Atezolizumab plus bevacizumab: A novel breakthrough in hepatocellular carcinoma. Clin. Cancer Res., 2021, 27(7), 1827-1829.
[http://dx.doi.org/10.1158/1078-0432.CCR-20-4706] [PMID: 33472912]
[http://dx.doi.org/10.1158/1078-0432.CCR-20-4706] [PMID: 33472912]
[20]
Hu, J.; Bao, Q.; Cao, G.; Zhu, X.; Yang, R.; Ji, X.; Xu, L.; Zheng, K.; Li, W.; Xing, B.; Wang, X. Hepatic arterial infusion chemotherapy using oxaliplatin plus 5-fluorouracil versus transarterial chemoembolization/embolization for the treatment of advanced hepatocellular carcinoma with major portal vein tumor thrombosis. Cardiovasc. Intervent. Radiol., 2020, 43(7), 996-1005.
[http://dx.doi.org/10.1007/s00270-019-02406-3] [PMID: 31974744]
[http://dx.doi.org/10.1007/s00270-019-02406-3] [PMID: 31974744]
[21]
Lyu, N.; Kong, Y.; Mu, L.; Lin, Y.; Li, J.; Liu, Y.; Zhang, Z.; Zheng, L.; Deng, H.; Li, S.; Xie, Q.; Guo, R.; Shi, M.; Xu, L.; Cai, X.; Wu, P.; Zhao, M. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J. Hepatol., 2018, 69(1), 60-69.
[http://dx.doi.org/10.1016/j.jhep.2018.02.008] [PMID: 29471013]
[http://dx.doi.org/10.1016/j.jhep.2018.02.008] [PMID: 29471013]
[22]
Gourd, K.; Lai, C.; Reeves, C. ESMO virtual congress 2020. Lancet Oncol., 2020, 21(11), 1403-1404.
[http://dx.doi.org/10.1016/S1470-2045(20)30585-4] [PMID: 32979983]
[http://dx.doi.org/10.1016/S1470-2045(20)30585-4] [PMID: 32979983]
[23]
Lyu, N.; Lin, Y.; Kong, Y.; Zhang, Z.; Liu, L.; Zheng, L.; Mu, L.; Wang, J.; Li, X.; Pan, T.; Xie, Q.; Liu, Y.; Lin, A.; Wu, P.; Zhao, M. FOXAI: A phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma. Gut, 2018, 67(2), 395.1-396.
[http://dx.doi.org/10.1136/gutjnl-2017-314138] [PMID: 28592441]
[http://dx.doi.org/10.1136/gutjnl-2017-314138] [PMID: 28592441]
[24]
Xu, J.; Zhang, Y.; Jia, R.; Yue, C.; Chang, L.; Liu, R.; Zhang, G.; Zhao, C.; Zhang, Y.; Chen, C.; Wang, Y.; Yi, X.; Hu, Z.; Zou, J.; Wang, Q. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: An open-label, dose escalation and expansion study. Clin. Cancer Res., 2019, 25(2), 515-523.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-2484] [PMID: 30348638]
[http://dx.doi.org/10.1158/1078-0432.CCR-18-2484] [PMID: 30348638]
[25]
Hassan, E.A.; Ahmed, E.H.; Nafee, A.M.; El-Gafary, N.; Hetta, H.F.; El-Mokhtar, M.A. Regulatory T Cells, IL10 and IL6 in HCV related hepatocellular carcinoma after transarterial chemoembolization (TACE). Egypt. J. Immunol., 2019, 26(1), 69-78.
[PMID: 31332997]
[PMID: 31332997]
[26]
Shigeta, K.; Datta, M.; Hato, T.; Kitahara, S.; Chen, I.X.; Matsui, A.; Kikuchi, H.; Mamessier, E.; Aoki, S.; Ramjiawan, R.R.; Ochiai, H.; Bardeesy, N.; Huang, P.; Cobbold, M.; Zhu, A.X.; Jain, R.K.; Duda, D.G. Dual programmed death receptor‐1 and vascular endothelial growth factor receptor‐2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma. Hepatology, 2020, 71(4), 1247-1261.
[http://dx.doi.org/10.1002/hep.30889] [PMID: 31378984]
[http://dx.doi.org/10.1002/hep.30889] [PMID: 31378984]
[27]
Chen, K.; Luo, C.P.; Ge, D.X.; Wang, K.L.; Luo, Q.; Li, Y.Z.; You, X.M.; Xiang, B.D.; Li, L.Q.; Ma, L.; Zhong, J.H. Case report: Conversion therapy to permit resection of initially unresectable hepatocellular carcinoma. Front. Oncol., 2022, 12, 946693.
[http://dx.doi.org/10.3389/fonc.2022.946693] [PMID: 36276151]
[http://dx.doi.org/10.3389/fonc.2022.946693] [PMID: 36276151]
[28]
Huang, J.; Huang, W.; Zhan, M.; Guo, Y.; Liang, L.; Cai, M.; Lin, L.; He, M.; Lian, H.; Lu, L.; Zhu, K. Drug-eluting bead transarterial chemoembolization combined with FOLFOX-based hepatic arterial infusion chemotherapy for large or huge hepatocellular carcinoma. J. Hepatocell. Carcinoma, 2021, 8, 1445-1458.
[http://dx.doi.org/10.2147/JHC.S339379] [PMID: 34858889]
[http://dx.doi.org/10.2147/JHC.S339379] [PMID: 34858889]
[29]
Kudo, M. A new treatment option for intermediate-stage hepatocellular carcinoma with high tumor burden: Initial lenvatinib therapy with subsequent selective TACE. Liver Cancer, 2019, 8(5), 299-311.
[http://dx.doi.org/10.1159/000502905] [PMID: 31768341]
[http://dx.doi.org/10.1159/000502905] [PMID: 31768341]
[30]
Fu, Z.; Li, X.; Zhong, J.; Chen, X.; Cao, K.; Ding, N.; Liu, L.; Zhang, X.; Zhai, J.; Qu, Z. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): A retrospective controlled study. Hepatol. Int., 2021, 15(3), 663-675.
[http://dx.doi.org/10.1007/s12072-021-10184-9] [PMID: 33877527]
[http://dx.doi.org/10.1007/s12072-021-10184-9] [PMID: 33877527]
[31]
Zhao, C.; Zhao, Z.; Wang, Z.; Hu, L.; Wang, H.; Fang, Z. Supervillin promotes tumor angiogenesis in liver cancer. Oncol. Rep., 2020, 44(2), 674-684.
[http://dx.doi.org/10.3892/or.2020.7621] [PMID: 32468064]
[http://dx.doi.org/10.3892/or.2020.7621] [PMID: 32468064]
[32]
Voron, T.; Colussi, O.; Marcheteau, E.; Pernot, S.; Nizard, M.; Pointet, A.L.; Latreche, S.; Bergaya, S.; Benhamouda, N.; Tanchot, C.; Stockmann, C.; Combe, P.; Berger, A.; Zinzindohoue, F.; Yagita, H.; Tartour, E.; Taieb, J.; Terme, M. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J. Exp. Med., 2015, 212(2), 139-148.
[http://dx.doi.org/10.1084/jem.20140559] [PMID: 25601652]
[http://dx.doi.org/10.1084/jem.20140559] [PMID: 25601652]
[33]
Liu, H.; Qin, X.; Xu, Z.; Wu, M.; Lu, T.; Zhou, S.; Yao, N.; Liu, S.; Shao, Y.; Han, Z. Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: A retrospective study in China. Front. Genet., 2022, 13, 1000448.
[http://dx.doi.org/10.3389/fgene.2022.1000448] [PMID: 36160021]
[http://dx.doi.org/10.3389/fgene.2022.1000448] [PMID: 36160021]
[34]
Markham, A.; Keam, S.J. Camrelizumab: First global approval. Drugs, 2019, 79(12), 1355-1361.
[http://dx.doi.org/10.1007/s40265-019-01167-0] [PMID: 31313098]
[http://dx.doi.org/10.1007/s40265-019-01167-0] [PMID: 31313098]
[35]
You, R.; Xu, Q.; Wang, Q.; Zhang, Q.; Zhou, W.; Cao, C.; Huang, X.; Ji, H.; Lv, P.; Jiang, H.; Lu, Y.; Jin, Y.; Li, Y.; Cheng, L.; Wang, W.; Xu, H.; Zhu, X.; Yin, G. Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study. Front. Oncol., 2022, 12, 816198.
[http://dx.doi.org/10.3389/fonc.2022.816198] [PMID: 35982962]
[http://dx.doi.org/10.3389/fonc.2022.816198] [PMID: 35982962]
[36]
Finn, R.S.; Qin, S.; Ikeda, M.; Galle, P.R.; Ducreux, M.; Kim, T.Y.; Kudo, M.; Breder, V.; Merle, P.; Kaseb, A.O.; Li, D.; Verret, W.; Xu, D.Z.; Hernandez, S.; Liu, J.; Huang, C.; Mulla, S.; Wang, Y.; Lim, H.Y.; Zhu, A.X.; Cheng, A.L. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med., 2020, 382(20), 1894-1905.
[http://dx.doi.org/10.1056/NEJMoa1915745] [PMID: 32402160]
[http://dx.doi.org/10.1056/NEJMoa1915745] [PMID: 32402160]
[37]
Tohyama, O.; Matsui, J.; Kodama, K.; Hata-Sugi, N.; Kimura, T.; Okamoto, K.; Minoshima, Y.; Iwata, M.; Funahashi, Y. Antitumor activity of lenvatinib (e7080): An angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J. Thyroid Res., 2014, 2014, 1-13.
[http://dx.doi.org/10.1155/2014/638747] [PMID: 25295214]
[http://dx.doi.org/10.1155/2014/638747] [PMID: 25295214]
[38]
Personeni, N.; Pressiani, T.; Rimassa, L. Lenvatinib for the treatment of unresectable hepatocellular carcinoma: Evidence to date. J. Hepatocell. Carcinoma, 2019, 6, 31-39.
[http://dx.doi.org/10.2147/JHC.S168953] [PMID: 30775342]
[http://dx.doi.org/10.2147/JHC.S168953] [PMID: 30775342]
[39]
Ryder, S.D.; Rizzi, P.M.; Metivier, E.; Karani, J.; Williams, R. Chemoembolisation with lipiodol and doxorubicin: Applicability in British patients with hepatocellular carcinoma. Gut, 1996, 38(1), 125-128.
[http://dx.doi.org/10.1136/gut.38.1.125] [PMID: 8566839]
[http://dx.doi.org/10.1136/gut.38.1.125] [PMID: 8566839]
[40]
Ebied, O.M.; Federle, M.P.; Carr, B.I.; Pealer, K.M.; Li, W.; Amesur, N.; Zajko, A. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer, 2003, 97(4), 1042-1050.
[http://dx.doi.org/10.1002/cncr.11111] [PMID: 12569604]
[http://dx.doi.org/10.1002/cncr.11111] [PMID: 12569604]
[41]
Liao, J.; Xiao, J.; Zhou, Y.; Liu, Z.; Wang, C. Effect of transcatheter arterial chemoembolization on cellular immune function and regulatory T cells in patients with hepatocellular carcinoma. Mol. Med. Rep., 2015, 12(4), 6065-6071.
[http://dx.doi.org/10.3892/mmr.2015.4171] [PMID: 26239573]
[http://dx.doi.org/10.3892/mmr.2015.4171] [PMID: 26239573]
